Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer

Table 4 Perioperative treatment-related adverse events in group immune checkpoint inhibitor and group non-immune checkpoint inhibitor, n (%)

Variable	Group ICI (n = 53)						Group non-ICI (n = 29)
	0	I	II	III	V	Total	0	I	II	III	V	Total	P value
Leucopenia	38	9	2	2	2	15 (28.3)	22	3	2	1	1	7 (24.1)	0.684
Neutropenia	35	10	5	2	1	18 (34.0)	21	3	3	2	0	8 (27.6)	0.553
Anemia	40	9	3	1	0	13 (24.5)	24	2	3	0	0	5 (17.2)	0.446
Thrombocytopenia	51	1	1	0	0	2 (3.8)	29	0	0	0	0	0 (0.0)	0.537
Serum AST/ALT increase	38	10	2	2	1	15 (28.3)	21	6	2	0	0	8 (27.6)	0.945
Elevated bilirubin index	49	3	1	0	0	4 (7.5)	27	2	0	0	0	2 (6.9)	1.000
Electrolyte disturbance	46	6	0	1	0	7 (13.2)	27	2	0	0	0	2 (6.9)	0.614
Serum creatinine increase	50	3	0	0	0	3 (5.7)	29	0	0	0	0	0 (0.0)	0.490
Hyper- or hypothyroidism	46	3	2	0	0	5 (9.4)	29	0	0	0	0	0 (0.0)	0.221
Myocardial enzyme increase	49	4	0	0	0	4 (7.5)	29	0	0	0	0	0 (0.0)	0.327
Pneumonia	53	0	0	0	0	0 (0.0)	29	0	0	0	0	0 (0.0)	NA
Adrenocortical insufficiency	52	0	0	1	0	1 (1.9)	29	0	0	0	0	0 (0.0)	1.000
Nausea/vomiting	40	9	1	1	2	13 (24.5)	23	2	1	1	2	6 (20.7)	0.694
Grade 0	-	-	-	-	-	28 (52.8)	-	-	-	-	-	17 (58.6)	0.967
Grade I	-	-	-	-	-	8 (15.1)	-	-	-	-	-	4 (13.8)	-
Grade II	-	-	-	-	-	5 (9.4)	-	-	-	-	-	3 (10.3)	-
Grade III	-	-	-	-	-	6 (11.3)	-	-	-	-	-	2 (6.9)	-
Grade IV	-	-	-	-	-	6 (11.3)	-	-	-	-	-	3 (10.3)	-
Overall rate	-	-	-	-	-	25 (47.2)	-	-	-	-	-	12 (41.4)	0.614
Any grade	-	-	-	-	-	41 (77.4)	-	-	-	-	-	23 (82.8)	0.564

ICI: Immune checkpoint inhibitor; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.